Drug & Device Law

JANUARY 15, 2024

That is significant because, unlike (now) every other state in the country, since 1987 Pennsylvania precedent prohibited defendants from introducing evidence of their compliance with government and/or industry standards (“standards compliance” or “compliance” evidence, for short) in strict liability design defect cases – generally.

Compliance 52

Compliance Government FDA Compliance Production 52

Drug & Device Law

MARCH 19, 2024

Moreover, the defense prevailed in Hodges : The plaintiffs next argue that the trial justice erred in restricting the jury’s use of the evidence it introduced concerning certain government reports filed by [defendant] that detailed patients’ negative experiences after taking [the drug]. at 1228 (emphasis added).

FDA 52

FDA FDA Compliance FDA Approval Production 52

Drug & Device Law

JULY 26, 2023

2018), holding (as discussed here ) that New Jersey multi-county mass-tort litigation will henceforth be governed exclusively by New Jersey law, no matter where the plaintiff resided. That’s not likely to happen anymore because in 2018 the same court issued In re Accutane Litigation , 194 A.3d 3d 503, 523 (N.J. at 523-24. at *14-15. [I]n

Compliance 52

Compliance FDA Compliance FDA Clinical Trials 52